Mirum Pharmaceuticals: Nothing Stops This Train (But The Technicals) (NASDAQ:MIRM)

Mirum Pharmaceuticals ( MIRM ) just reported its 4Q, its full year topline clocking in at $521 million , up 55% from the prior year. Though the quarter's net income disappointed, the call cemented a banner year and providedSean Daly writes on ETFs, biotech and FINTECH solutions in the banking space. He teaches international finance and financial risk management at Pace University and was a visiting lecturer at Princeton University from 2005 to 2009. He was educated at Columbia University. He has also writte ...